EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Evaluating Neutralizing Antibody Titers by Recombinant Feline Calicivirus with Heterologous Capsid Protein VP1

Yang Wang, Wei Lin, Yue Zhang, Hongling He, Yueming Wang, Saisai Li, Qiuyuan Zhang, Shile Huang iD, Jun Luo iD, Xiaofeng Guo iD

Animals · 2026-04-17 · 16 (8) · 1237

DOI: 10.3390/ani16081237 ↗

At a glance

Journal article in Animals, published online on 2026-04-17. Written by Yang Wang and 9 co-authors. Institution: College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China. 30 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, National Key Research and Development Program of China, Natural Science Foundation of Guangdong Province.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Feline calicivirus (FCV) is a major pathogen that threatens feline health worldwide. Its global prevalence, extensive genetic variability, and limited cross-protection among strains present significant challenges for vaccine development. In this study, an infectious clone of the FCV-GDJM202201 strain was constructed using the eukaryotic expression plasmid pcDNA3.1 under the control of the cytomegalovirus (CMV) promoter. The rescued virus, rGDJM-A4822T, exhibited growth kinetics comparable to those of the parental strain in vitro. Subsequently, two recombinant viruses, rGDJM-VP1JL and rGDJM-VP1SH, were generated by replacing the VP1 gene in the GDJM202201 backbone with those from heterologous FCV strains. Notably, these recombinant viruses exhibited reduced viral titers compared to rGDJM-A4822T. Finally, neutralization assays revealed differential neutralizing antibody titers among the recombinant FCVs, with rGDJM-A4822T inducing higher neutralizing antibody titers and cross-neutralizing activity. Collectively, this study establishes an FCV infectious clone that can be used to rescue recombinant viruses carrying heterologous VP1 proteins and to evaluate neutralizing antibody responses.

Subjects

Author keywords

VP1 genefeline calicivirusgrowth kineticsinfectious cloneneutralizing antibody

Authors and institutions

  • College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
  • Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932, USA.
  • Department of Hematology and Oncology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932, USA.
  • Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932, USA.

ORCID profiles: Shile Huang, Jun Luo, Xiaofeng Guo

Funding

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Natural Science Foundation of Guangdong Province
  • Specific University Discipline Construction Project

Cite

APA

Wang, Y., Lin, W., Zhang, Y., He, H., Wang, Y., Li, S., Zhang, Q., Huang, S., Luo, J., & Guo, X. (2026). Evaluating Neutralizing Antibody Titers by Recombinant Feline Calicivirus with Heterologous Capsid Protein VP1. Animals, 16(8), 1237. https://doi.org/10.3390/ani16081237

Vancouver

Wang Y, Lin W, Zhang Y, He H, Wang Y, Li S, et al. Evaluating Neutralizing Antibody Titers by Recombinant Feline Calicivirus with Heterologous Capsid Protein VP1. Animals. 2026;16(8):1237. doi:10.3390/ani16081237

BibTeX
@article{Wang2026,
  author = {Wang, Yang and Lin, Wei and Zhang, Yue and He, Hongling and Wang, Yueming and Li, Saisai and Zhang, Qiuyuan and Huang, Shile and Luo, Jun and Guo, Xiaofeng},
  title = {Evaluating Neutralizing Antibody Titers by Recombinant Feline Calicivirus with Heterologous Capsid Protein VP1},
  journal = {Animals},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {1237},
  doi = {10.3390/ani16081237}
}
Start for free →